Immunotherapies targeting the immune checkpoint receptors programmed cell death receptor 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) have resulted in significantly improved clinical outcomes in patients with metastatic melanoma [1,2,3] and are now standard of care treatment [4]. This evidence concerns the gene CTLA4 and metastatic melanoma.